Xeris Biopharma Holdings Inc. Business Model Research Guide
Direct answer: This business model research guide covers how to verify Xeris Biopharma Holdings Inc.'s revenue model, customer economics, cost structure, and competitive advantages from primary SEC filings. Use each section as a research checklist rather than a finished analysis. Every claim must be traced to a current 10-K, 10-Q, or 8-K before reaching a conclusion.
What Do the Reported Numbers Say About the Xeris Biopharma Holdings Inc. Business Model?
Xeris Biopharma Holdings Inc. has not broken its revenue out by segment, product or region in a way Swoopr can read from its filings, so this table shows the economics of the whole business: what it earned, what it kept and what it spent on equipment, for the fiscal years ended December 31, 2022 to December 31, 2025.
| Fiscal year | Revenue | Growth | Operating margin | Net margin |
|---|---|---|---|---|
| FY2022 | $110 million | n/a | -74.3% | -85.9% |
| FY2023 | $164 million | +48.7% | -26.8% | -38.0% |
| FY2024 | $203 million | +23.9% | -16.6% | -27.0% |
| FY2025 | $292 million | +43.7% | 8.5% | 0.2% |
"Not reported" means the company filed no value under the standard tag, not that the amount was zero. Source: SEC EDGAR: Xeris Biopharma Holdings, Inc. Form 10-K filed March 2, 2026.
Revenue model
For Xeris Biopharma Holdings Inc., the revenue model review should cover pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure.
Customer economics
For Xeris Biopharma Holdings Inc., the customer economics review should cover who pays, why they pay, contract or transaction structure, concentration and switching behavior.
Cost structure
For Xeris Biopharma Holdings Inc., the cost structure review should cover Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products..
Scale and competitive advantage
For Xeris Biopharma Holdings Inc., the scale and competitive advantage review should cover distribution, installed base, data, regulation, brand, network effects or cost position where supported.
Capital intensity
For Xeris Biopharma Holdings Inc., the capital intensity review should cover working capital, capex, acquisitions and other reinvestment required to sustain growth.
Research Checklist
- Product Adoption: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether product adoption is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Procedure Or Prescription Volumes: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether procedure or prescription volumes is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Clinical And Regulatory Milestones: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether clinical and regulatory milestones is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Reimbursement: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether reimbursement is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- New Indications: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether new indications is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Capacity And Commercial Execution: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether capacity and commercial execution is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Patients: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether patients is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Providers: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether providers is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
- Hospitals: For Xeris Biopharma Holdings Inc. (XERS), determine from current primary sources whether hospitals is a material business model; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
Related Research
Source Standard
The latest annual report, quarterly filings, material 8-Ks and official investor-relations disclosures are the primary sources. Do not infer company-specific figures from the sector framework.
References
Company financial disclosures, SEC filings and investor-relations materials are the authoritative sources for financial figures cited on this page. Individual company SEC filings are available at SEC EDGAR.